Articles tagged with Alzheimer Disease
Researchers at Beth Israel Deaconess Medical Center found that an anti-seizure drug can normalize abnormal brain wave frequencies in patients with mild Alzheimer's disease. The study suggests that suppressing seizure-like activity may help patients, and could be a new avenue for treating the disease.
Research found no link between proton pump inhibitors and increased risk of dementia in people 75-years-old or older. However, frequent PPI use was associated with higher rates of depression, heart disease, and other health conditions. Regular PPI use also showed a decreased risk of cognitive decline.
Florida Atlantic University has received a $1 million grant to establish the Comprehensive Center for Brain Health, which will focus on reducing risk of neurodegenerative diseases through personalized prevention plans. The center aims to identify individualized strategies to build a better brain as people age.
Researchers at the University of Cambridge have designed antibodies to stop the production of protein deposits linked to Alzheimer's disease. The antibodies, developed using computer-based methods, were tested in test tubes and nematode worms, showing almost complete elimination of toxic pathogens.
Researchers at Temple University Health System found that extra-virgin olive oil reduces brain inflammation and activates autophagy, preserving synaptic integrity and reducing amyloid plaques and neurofibrillary tangles. This may provide a potential prevention or treatment strategy for Alzheimer's disease.
Researchers have developed systems-pharmacological modeling to analyze and predict the dynamics of new drugs for Alzheimer's disease. The models can accurately match cerebrospinal fluid analysis results with brain processes, allowing for optimal drug administration and therapy selection.
Researchers at The University of Nottingham have discovered that a plant extract from Carpolobia lutea may help protect brain chemical messengers in people with Alzheimer's disease. The study found the extract to be highly effective in preventing the breakdown of acetylcholine, a neurotransmitter linked to memory and learning.
Japanese scientists have developed a method to isolate and identify active compounds in plant medicines, which accurately accounts for drug behavior in the body. They identified several active compounds from Drynaria Rhizome that improve memory and reduce disease characteristics in a mouse model of Alzheimer's disease.
A study published in The Journal of the American Medical Association found that elevated brain amyloid plaques are an early precursor to Alzheimer's disease, which can lead to faster mental decline. The research suggests that intervening against amyloid levels could slow or even stop the onset of the disease.
A study of cognitively normal individuals found that those with elevated brain amyloid levels were more likely to experience cognitive decline over a median of 3.1 years. The research suggests that preclinical Alzheimer's disease may represent the pre-symptomatic stage of AD.
A single dual time-point PET scan can identify two important biomarkers of Alzheimer's disease: neuronal injury and amyloid load. This non-invasive method shows promise for early diagnosis and personalized treatment.
A new USC study found that a poor diet, combined with the ApoE4 gene variant, can increase the development of Alzheimer's plaques in mice. The study suggests that lifestyle factors such as diet and exercise may play a role in regulating the risk of Alzheimer's disease.
Researchers discovered anthranilic acid as a circulating compound associated with the risk of developing dementia and Alzheimer's disease. The study identified promising findings in new biological pathways and potential drug targets for prevention.
Researchers analyzed BACE_1, a critical enzyme in Alzheimer's disease, and proposed modifications to increase inhibitor bioavailability. Novel nanoparticle techniques are also being explored to destroy amyloid plaques, offering new hope for AD treatment.
Dementia with Lewy bodies affects 1.4 million Americans, often misdiagnosed as Alzheimer's or Parkinson's disease. The new guidelines provide detailed guidance for diagnosing and treating the condition, which includes symptoms like visual hallucinations and sleep difficulties.
Researchers at Brigham and Women's Hospital discovered a link between complement C3 signaling and neurodegeneration in Alzheimer's disease. In preclinical models, mice with C3 deficiency showed improved cognitive function despite accumulating amyloid plaques, suggesting modulating immune response could combat the disease.
A phase 2 clinical trial of scyllo-inositol found the treatment to be safe and tolerable in young adults with Down syndrome. The study suggests further investigation into its potential for treating Alzheimer's disease in this population.
A new study suggests that cognitive tests can detect early Alzheimer's disease in people without symptoms. The study found that individuals with amyloid plaques performed worse on neuropsychological tests than those without, highlighting the potential for routine cognitive screenings to identify preclinical Alzheimer's disease.
Researchers found that abnormal proteins in Alzheimer's, Parkinson's, and Huntington's diseases cause the same type of vesicle damage, potentially leading to effective treatments for multiple neurodegenerative diseases.
Scientists at NERF have discovered a novel method to measure respiration dynamics, revealing that mice compare the strength of smells obtained through both nostrils for odor source localization. This process involves information transfer between brain hemispheres and has valuable implications for Alzheimer's research.
Researchers develop a cost-effective method to produce Aβ42 peptide, a key player in Alzheimer's disease, using isotope labeling and FPLC. This approach simplifies NMR-based structural studies of the peptide, paving the way for deeper understanding of AD.
Researchers found that age-dependent protein aggregates can induce Aβ aggregation, leading to Alzheimer's disease. The study identified proteins like PAR-5 as potential therapeutic targets, offering new avenues for preventative research.
Regular physical activity can improve daily living and mobility in older adults with Alzheimer's, as well as reduce the risk of developing the disease. The study suggests that exercising may be a practical and accessible intervention for preventing and managing Alzheimer's disease.
A study by Karolinska Institutet measures how tau deposits spread through the brain over time, revealing individual variations in size and speed of spread. Large amounts of tau can be linked to episodic memory impairment, improving understanding of Alzheimer's disease.
The National Institute on Aging has renewed Penn Medicine's Alzheimer's disease genetics data repository, providing $7.7 million in funding over five years. The site gathers and organizes genetic data to aid researchers in understanding the disease's origins and potential prevention and cure strategies.
JAX researcher Catherine Kaczorowski will receive a $2.7M federal grant to investigate the complex processes involved in both healthy aging and Alzheimer's disease through genomic studies. The goal is to identify genetic factors, mechanisms underlying normal aging, and potential targets for intervention against Alzheimer's.
Researchers discovered brain structure changes in older adults without noticeable memory problems, using the Montreal Cognitive Assessment test. These findings suggest that brain imaging may predict dementia years prior to diagnosis.
Researchers analyzed DNA samples from over 95,000 participants to examine the association between Alzheimer's disease and low BMI. The study found no causal relationship, suggesting that individuals with Alzheimer's disease are more likely to have low BMIs due to weight loss in the early stages of the disease.
Ben-Gurion University researchers found that SIRT6 protein levels are significantly lower in Alzheimer's patients and contribute to the onset of the disease. The study suggests a link between low SIRT6 levels and DNA damage accumulation, which may lead to neurodegenerative diseases.
A new group language intervention has been developed to help individuals with primary progressive aphasia (PPA) maintain their communication abilities. The 10-week intervention includes working on language activities and learning communication strategies, resulting in improved or unchanged communication assessments for patients.
A gene mutation called the Met allele may accelerate memory and thinking skills decline in people at risk for Alzheimer's disease, according to a study published in Neurology. Researchers found that individuals with the mutation lost cognitive skills more rapidly than those without it.
Researchers have identified 'silent seizures' in the brains of patients with Alzheimer's disease, a discovery that could lead to new treatments. The findings suggest that these non-convulsive hippocampal seizures may contribute to or accelerate the degenerative process underlying the disease.
Li-Ru Zhao, PhD, MD, receives the 2017 Bernard Sanberg Memorial Award for her research contributions in acute and chronic stroke, vascular dementia, traumatic brain injury, and Alzheimer's disease. Her work has significantly advanced our understanding of SCF and G-CSF in slowing Alzheimer's progression.
Researchers recorded seizure-like activity in the hippocampus of two patients with Alzheimer's disease, which may contribute to cognitive symptoms. The findings suggest that targeting this dysfunction could lead to new treatments to reduce symptoms or alter the course of the disease.
Tramiprosate acts to inhibit the production of neurotoxic beta amyloid oligomers by enveloping the amyloid peptide to prevent its misfolding. This novel mechanism prevents the self-assembly of misfolded proteins into beta amyloid oligomers, leading to neuronal toxicity and clinical progression in Alzheimer's disease.
Researchers discovered two genes, UNC5C and ENC1, associated with aging individuals' better memory and brain function despite accumulated brain pathologies. The study used genetic analysis of 979 organ donors' brain tissue to identify these genes and provide potential new targets for developing medications to enhance brain resilience.
Researchers found that low levels of the 'memory protein' NPTX2 are associated with reduced levels of cognition and memory loss in Alzheimer's disease. The study suggests that the combination of low NPTX2 and amyloid plaques disrupts neural activity, leading to cognitive failure.
After a head injury, the brain can form new connections between damaged areas, known as hyperconnections. While this adaptation may provide short-term benefits, it can also lead to chronic inefficiencies and strain the brain's resources. Chronic inefficiencies may cascade into serious brain disorders, including Alzheimer's Disease.
Researchers at UCI have developed a method to generate human microglia cells from skin stem cells, providing a powerful new approach to study and potentially treat neurological diseases like Alzheimer's. This discovery marks an important step in using induced pluripotent stem (iPS) cells for targeted approaches.
A study by the University of Gothenburg reveals a connection between long-term concussion symptoms and nerve cell damage in hockey players. The research suggests that there may be two separate conditions involved, with no evidence of plaque formation like in Alzheimer's disease.
Researchers have mapped transport in mammalian axons for the first time, revealing a crucial protein called MAP2 that regulates molecular movement. The discovery provides new insights into neurodegenerative diseases such as Alzheimer's and Parkinson's.
Yuna Ayala's research team discovers how TDP-43 protein causes damaging plaque buildup in neurodegenerative diseases like ALS and frontotemporal dementia. They found that phosphorylation regulates TDP-43's activity, location, and processing, which may be crucial for cellular metabolism.
Researchers have discovered an antibody that can detect tau in the serum of patients with tauopathies, a neurodegenerative disorder characterized by toxic protein clumps. The antibody, HJ8.5, has shown promise in increasing tau levels in human patients and mouse models, potentially paving the way for new treatments.
A study published in the Journal of Alzheimer's Disease found that individuals with a genetic predisposition to Alzheimer's disease had difficulty distinguishing novel figures called Greebles, even when others could not. This method may allow for earlier detection and potential treatment of the disease.
Researchers found a 30% increased risk of pneumonia in patients with Alzheimer's disease taking benzodiazepines, particularly within the first 30 days of treatment. The study suggests that benzodiazepines' sedative nature may increase the risk of pneumonia by increasing saliva or food aspiration into the lungs.
Researchers at Oregon State University developed a software to analyze social media comments and found that 51% of tweets about Alzheimer's disease contained stigma. The system may help combat negative attitudes and promote positive experiences of people with dementia.
Researchers are testing an anti-amyloid drug on people with elevated amyloid levels but no cognitive decline. The goal is to identify an early stage of the disease and delay onset by five years by 2025, which could save billions in healthcare costs.
Researchers at Oregon State University have discovered a new function for rapamycin that may help prevent neurologic damage and some related diseases. The compound appears to stop cellular senescence, a stage cells reach where they get old and start secreting damaging substances.
A recent study found that psychiatric disorders do not increase the risk of Alzheimer's disease, contrary to previous assumptions. However, the study suggests that some psychiatric disorders may be prodromal symptoms of Alzheimer's disease, highlighting the importance of proper differential diagnostics.
Researchers identify Ephexin5 as a key regulator of brain cell connections in Alzheimer's disease, finding that removing the protein prevents deficits in animal models. By targeting Ephexin5, drugs may be developed to prevent or treat symptoms of the disorder.
Researchers at Brigham and Women's Hospital have discovered a new genetic variant linked to Tau pathology in Alzheimer's disease. The study, published in Molecular Psychiatry, highlights the potential for targeting the protein tyrosine phosphatase receptor-type delta (PTPRD) gene as a therapeutic strategy.
A new gene variant has been identified in the PTPRD gene that is associated with the accumulation of neurofibrillary tangles (NFTs) in the brain. The study found that this variant affects more than one mechanism of tangle accumulation and may be a key target for developing therapies targeting Tau pathology.
Researchers discovered that thin parts of neuronal membranes are vulnerable to amyloid-beta protein, which builds up in Alzheimer's disease. The study found that thinner membrane fragments allow plaque to penetrate the cell, leading to cell death and memory loss.
Researchers Claudia Kawas and Kristine Yaffe received the 2017 Potamkin Prize for their work on Alzheimer's disease epidemiology in the oldest-old population. Their studies highlight the critical role of modifiable risk factors in dementia prevention.
Researchers found that unsaturated fatty acids were significantly decreased in Alzheimer's brains compared to healthy patients, contradicting previous assumptions. The study suggests a crucial role for fats in dementia onset and progression, with surprising findings on omega-3s and their impact on the disease.
A research team developed a polygenic hazard score to estimate an individual's Alzheimer disease risk based on their genetic data and age. The score predicted those with the highest risk were several times more likely to develop AD, with earlier expected onset by up to 10 years.
Researchers at Rockefeller University have discovered that changes in the vascular system and a plasma component called Factor XII may trigger Alzheimer's disease. The study suggests that targeting this process could lead to early diagnosis and new treatments for the condition.
Researchers have created a polygenic hazard score that predicts age-specific risk of developing Alzheimer's disease based on genetic information. The score identifies individuals with higher genetic risk who develop AD at an earlier age, even among those without the APOE E4 allele.
A study published in PLOS Medicine found that six unsaturated fatty acids are associated with Alzheimer's disease cognitive symptoms and neuropathology. The researchers analyzed brain tissue samples from older individuals with healthy brains, those with tau or amyloid proteins but no memory problems, and those with Alzheimer's disease.
A common genetic variant, TMEM106B, accelerates normal brain aging by up to 12 years in people aged 65+, highlighting potential new targets for preventing age-associated brain disorders like Alzheimer's disease. Researchers also identified another variant associated with brain aging within the progranulin gene.